Effectiveness of Baricitinib and Remdesivir in COVID-19 Treatment An early release, peer-reviewed clinical trial published by the National Institute of Health investigates the combination of baricitinib and remdesivir when used in people hospitalized with confirmed COVID-19 infection and shows promise Read More
Clinical characteristics This cross-sectional study examined racial/ethnic variation in nasal gene expression of trans-membrane serine protease 2 (TMPRSS2). Within the 305 individuals with tissue samples (nasal epithelium collected during 2015-2018),  TMPRSS2 expression was significantly higher in Black individuals compared with Read More
RCT’s of therapeutic interventions against COVID-19 In this journal article, the authors discuss the challenges that plagued us during the early days of the COVID-19 pandemic. When the pandemic emerged, clinicians were faced with an unknown virus and had very Read More
This randomized trial showed that hydroxychloroquine did not prevent presumed/confirmed COVID-19 when used as post-exposure prophylaxis within 4 days of high- or moderate-risk COVID-19 exposure. This randomized, double-blind, placebo-controlled trial occurred across the United States and parts of Canada Enrolled Read More
This randomized clinical trial showed that convalescent plasma therapy + standard treatment did not improve time to clinic improvement within 28 days compared to standard treatment alone in patients with severe or life-threatening COVID-19.  Patients were recruited from 7 medical Read More
This randomized, open-label trial found no significant difference in defined clinical outcomes between a 5 day vs 10 day course of remdesivir.  Inclusion criteria: >11 years of age, confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were Read More
This preliminary report from a double-blind, randomized, placebo-controlled study found remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection.  Enrollment for ACTT-1 began on February 21, Read More
  This was an open-label, randomized trial comparing clinical outcomes of those on triple combination therapy to those on lopinavir-ritonavir alone, which found that early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening Read More
The early results of this study suggest that higher chloroquine doses should not be recommended for critically ill patients with COVID-19 because of potential safety hazards, especially if combined with azithromycin and oseltamivir. In this parallel, double-masked, randomized clinical trial Read More
In this randomized control trial, health care providers were less likely to accurately recall information when overloaded with too much and too frequent communication during an emergency. Information delivered too frequently and/or repetitively through multiple communication channels can have a Read More

Get Involved with Indiana CTSI